$1.93
10.23%
Nasdaq, Tue, May 20 2025
ISIN
US00887A1051
Symbol
ALRN
Sector
Industry

Aileron Therapeutics, Inc. Stock price

$1.93
+0.15 8.43% 1M
-0.83 30.07% 6M
-0.37 16.09% YTD
-1.76 47.70% 1Y
-6.87 78.07% 3Y
-11.87 86.01% 5Y
-214.07 99.11% 10Y
Nasdaq, Closing price Tue, May 20 2025
-0.22 10.23%
ISIN
US00887A1051
Symbol
ALRN
Sector
Industry

Key metrics

Market capitalization $42.76m
Enterprise Value $80.34m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
P/B ratio (TTM) P/B ratio 8.71
Revenue (TTM) Revenue $0.00
EBIT (operating result TTM) EBIT $-26.52m
Free Cash Flow (TTM) Free Cash Flow $-23.20m
Cash position $7.43m
EPS (TTM) EPS $-2.86
Short interest 1.08%
Show more

Is Aileron Therapeutics, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,789 stocks worldwide.

Aileron Therapeutics, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

1 Analyst has issued a forecast Aileron Therapeutics, Inc.:

1x Buy
100%

Analyst Opinions

1 Analyst has issued a forecast Aileron Therapeutics, Inc.:

Buy
100%

Financial data from Aileron Therapeutics, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
- -
-
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 13 13
0% 0%
-
- Research and Development Expense 14 14
145% 145%
-
-27 -27
44% 44%
-
- Depreciation and Amortization - -
-
-
EBIT (Operating Income) EBIT -27 -27
43% 43%
-
Net Profit -61 -61
239% 239%
-

In millions USD.

Don't miss a Thing! We will send you all news about Aileron Therapeutics, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Aileron Therapeutics, Inc. Stock News

Neutral
PRNewsWire
4 months ago
Rebrand to Rein Therapeutics is representative of the Company's sole focus in developing therapies in orphan pulmonary and fibrosis indications, including two Phase 2-ready clinical assets Company shares to begin trading on Nasdaq under the trading symbol "RNTX" effective January 13, 2025 AUSTIN, Texas , Jan. 10, 2025 /PRNewswire/ -- Rein Therapeutics ("Rein") (NASDAQ: RNTX), formerly known as ...

Company Profile

Aileron Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of novel class of therapeutics for the treatment of cancer and other diseases. It focuses on its lead products candidate, ALRN-6924 which is a cell-permeating peptide that disrupts the interaction of p53 suppressors MDM2 and MDMX with tumor suppressor p53 to reactivate tumor suppression in non-mutant, or wild-type, p53 cancers. The company was founded by Gregory L. Verdine, Rosana Kapeller, Huw M. Nash, Joseph A. Yanchik III, and Loren David Walensky in June 2005 and is headquartered in Cambridge, MA.

Head office United States
CEO Brian Windsor
Employees 11
Founded 2001
Website www.reintx.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today